JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

DHR

216.47

+0.36%↑

Search

Intuitive Surgical Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

487.26 2.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

485.74

Max

489.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

45M

709M

Pardavimai

361M

2.9B

P/E

Sektoriaus vid.

63.278

84.243

Pelno marža

28.31

Darbuotojai

15,638

EBITDA

-60M

956M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+33.72% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-21

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-14B

178B

Ankstesnė atidarymo kaina

484.9

Ankstesnė uždarymo kaina

487.26

Naujienos nuotaikos

By Acuity

8%

92%

2 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Intuitive Surgical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-21 23:55; UTC

Karštos akcijos

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

2025-10-21 21:14; UTC

Uždarbis
Pagrindinės rinkos jėgos

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

2025-10-21 20:38; UTC

Uždarbis

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

2025-07-22 21:13; UTC

Uždarbis

Intuitive Surgical Logs Higher Profit, Revenue in 2Q

2026-01-23 16:07; UTC

Uždarbis

Intuitive Surgical Stock Beats Earnings Estimates. The Stock Is Barely Moving. -- Barrons.com

2026-01-23 12:58; UTC

Uždarbis

Intuitive Surgical Stock Rises on Earnings. What Wall Street Is Saying. -- Barrons.com

2026-01-22 21:11; UTC

Uždarbis

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

2026-01-22 21:11; UTC

Uždarbis

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

2026-01-22 21:10; UTC

Uždarbis

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q EPS $2.21 >ISRG

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Rev $2.87B >ISRG

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Net $794.8M >ISRG

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Adj EPS $2.53 >ISRG

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q Da Vinci Surgical Systems Shipped 532.00 >ISRG

2025-10-30 12:38; UTC

Uždarbis

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

2025-10-30 12:01; UTC

Uždarbis

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

2025-10-22 15:42; UTC

Uždarbis

Intuitive Surgical Stock Jumps on Earnings. Its Newest Surgical Robot Is Going Gangbusters. -- Barrons.com

2025-10-22 12:34; UTC

Uždarbis

Intuitive Surgical Stock Surges. Earnings Show It Can Maintain 'Bellwether Medtech Growth Status.' -- Barrons.com

2025-10-22 11:49; UTC

Uždarbis

Intuitive Surgical Stock Surges. Earnings Show It Can Maintain 'Bellwether Medtech Growth Status.' -- Barrons.com

2025-10-21 20:08; UTC

Uždarbis

Intuitive Surgical: Worldwide Da Vinci Procedure Growth of Approximately 17% to 17.5% in 2025, Compared to 17% in 2024 >ISRG

2025-10-21 20:08; UTC

Uždarbis

Intuitive Surgical: Non-GAAP Gross Profit Margin to Be Within a Range of 67% and 67.5% of Rev in 2025, Compared to 69.1% in 2024 >ISRG

2025-10-21 20:05; UTC

Uždarbis

Intuitive Surgical 3Q Rev $2.51B >ISRG

2025-10-21 20:05; UTC

Uždarbis

Intuitive Surgical 3Q Net $704.4M >ISRG

2025-10-21 20:05; UTC

Uždarbis

Intuitive Surgical 3Q Adj EPS $2.40 >ISRG

2025-10-21 20:05; UTC

Uždarbis

Intuitive Surgical 3Q Da Vinci Surgical Systems Shipped 427.00 >ISRG

2025-10-21 20:05; UTC

Uždarbis

Intuitive Surgical 3Q EPS $1.95 >ISRG

2025-07-22 20:14; UTC

Uždarbis

Intuitive Surgical Sees FY25 Non-GAAP Gross Profit Margin to Be Within Range of 66% and 67% >ISRG

2025-07-22 20:13; UTC

Uždarbis

Intuitive Surgical Sees FY25 Worldwide Da Vinci Procedure Growth of 15.5% to 17% >ISRG

2025-07-22 20:13; UTC

Uždarbis

Intuitive Surgical Grew Da Vinci Surgical System Installed Base to 10,488 Systems as of June 30 >ISRG

2025-07-22 20:05; UTC

Uždarbis

Intuitive Surgical 2Q Net $658.4M >ISRG

Akcijų palyginimas

Kainos pokytis

Intuitive Surgical Inc Prognozė

Kainos tikslas

By TipRanks

33.72% į viršų

12 mėnesių prognozė

Vidutinis 652.73 USD  33.72%

Aukščiausias 750 USD

Žemiausias 550 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Intuitive Surgical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

14

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

514.59 / 539.05Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

2 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Intuitive Surgical Inc

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
help-icon Live chat